Wockhardt’s Zaynich antibiotic surged stock by 75%. CEO Habil Khorakiwala cited its uniqueness; phase three trials end this fiscal year. Compared to Novo Nordisk’s Ozempic, Zaynich’s $25 billion potential counters global antibiotic resistance.
Warburg Pincus to evaluate buying majority stake in Nuvama Wealth: Report
Warburg Pincus may acquire a majority stake in Nuvama Wealth Management as PAG looks to sell its 54% holding, valued at $1.6 billion. JPMorgan and